Home › Resources › Webinars › From Qualitative to Quantitative: Experiences with a cfDNA Assay in Metastatic Breast Cancer
May 22, 2018
Sponsored by
Thermo Fisher Scientific

From Qualitative to Quantitative: Experiences with a cfDNA Assay in Metastatic Breast Cancer

Genome Webinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences discusses her team’s work using liquid biopsy technology for breast cancer research.

Sponsored by
Oct
23
Featured Webinar

Perspectives on Small RNA Sequencing: Challenges and Complications of Small RNA Library Prep

Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Cancer

  1. Foundation Medicine, Novartis Partner to Develop CDx for Oncology Drugs

  2. Thermo Fisher Scientific Gets CE-IVD Mark for NGS Cancer Test

  3. FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug

  4. Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

  5. Cancer Genetics, GeneCast Ink Cancer Test Distribution Deal

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.